Indications
Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Composition
- Active substance
- glycopyrronium bromide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tovanor Breezhaler
- Active substance
- glycopyrronium bromide
- ATC code
- R03BB06
- Group
- Respiratory system
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- Marketing authorisation holder
- Novartis Europharm Limited
- Status
- Authorised
- EU authorisation